Rodolfo Hrosz, will step down from his role effective 30 April 2025, to take up another position within the Sanofi group.

In the previous session, Indian markets ended in the red after the RBI MPC cut the repo rate by 25 basis points to 6 per cent ...

Nigeria's second-largest pharmaceutical company, GlaxoSmithKline (GSK), announced its exit from the country, ending its 51-year presence.Three months later, Sanofi, another leading pharmaceutical ...

At its annual Kinexions conference, Kinaxis ® (TSX:KXS), a global leader in end-to-end supply chain orchestration, announced the winners of its 2025 Kinaxis Customer Awards. Now in their seventh year, ...

In a report released today, Raj Jilka from Jefferies maintained a Buy rating on Sanofi (SNYNF – Research Report), with a price target of ...

The board of directors accepted Hrosz’s resignation during a meeting held on April 9 and expressed appreciation for his ...

Throughout the course of multiple sclerosis, gradually progressive neurologic impairment can occur, which has been called ...

Tolebrutinib is an oral, brain-penetrant, and bioactive Bruton’s tyrosine kinase inhibitor that modulates peripheral ...

The New England Journal of Medicine published results from the HERCULES phase 3 study demonstrating that tolebrutinib delayed disability ...

GSK pays ABL Bio $49.5M upfront for blood-brain barrier platform access, with potential $2.67B in milestone payments. Deal ...

From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry ...

Big Pharma has aimed some choice words at European countries in recent weeks, including calling the UK “uninvestable” and ...